Survival on Peritoneal Dialysis (PD) Versus Hemodialysis (HD) in China

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Baxter Healthcare Corporation
ClinicalTrials.gov Identifier:
NCT01413074
First received: June 16, 2011
Last updated: April 7, 2014
Last verified: August 2011
  Purpose

Primary Objective: The primary objective is to prospectively assess and compare survival in subjects with End Stage Renal Disease (ESRD) randomized to Peritoneal Dialysis (PD) or Hemodialysis (HD) treatment.

Secondary Objectives: The secondary objectives are to prospectively assess and compare the following parameters in subjects receiving PD or HD treatment:

  • Technique failure
  • Cause of death
  • Comorbidity status at baseline and changes throughout the study
  • Change in residual renal function (RRF)
  • Dialysis adequacy (i.e., Kt/Vurea)
  • Change in blood pressure, hemoglobin, and S-phosphate
  • Change in nutritional status
  • Occurrence of bacterial and other infections
  • Hospitalization, including number, duration, and underlying reason(s)
  • Systemic inflammation as assessed by high-sensitivity C reactive protein (hs-CRP)
  • Quality of life (QOL)

Safety Objectives: To compare the nature and frequency of adverse events (AEs) and serious adverse events (SAEs), including abnormal laboratory test findings with clinical significance, in subjects receiving PD or HD treatment.


Condition Intervention Phase
End Stage Renal Disease
Other: Peritoneal Dialysis treatment
Other: Hemodialysis treatment
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Multicenter, Open-Label, Interventional Study Comparing Survival in Subjects Receiving Peritoneal Dialysis vs Hemodialysis in China

Resource links provided by NLM:


Further study details as provided by Baxter Healthcare Corporation:

Primary Outcome Measures:
  • Assess and compare survival or all cause mortality in subjects undergoing PD or HD treatment [ Time Frame: 2-5 yrs. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Assess and compare technique failure [ Time Frame: 2-5 yrs. ] [ Designated as safety issue: No ]
    Technique failure is defined as a change of dialysis modality (PD to HD, or HD to PD) or death. However, a temporary transfer, defined as ≤ 6 weeks duration and ≤ 2 occasions per any 52-week period, will not be considered technique failure. The use of both modalities within a 7-day period for more than 4 consecutive weeks will be considered technique failure. Technique failure will be monitored in two ways: modality failure including deaths and technique failure not including deaths.

  • Residual Renal Function (RRF) [ Time Frame: 2-5 yrs ] [ Designated as safety issue: No ]
    RRF will be estimated if the subject's urine volume is ≥ 100 mL/24 h. RRF will be assessed by calculating GFR from a 24-h urine urea and creatinine collection and normalized to 1.73 m2 Body Surface Area. RRF will be measured at screening, visit 1 and every 12 weeks after visit 1 till the end of the study. Subjects who have a permanent modality transfer will be followed up for RRF (with the frequency of assessment determined by the modality they are switched to) until the end of the study, transplantation, stopping dialysis, lost to follow-up, or death.

  • Dialysis Adequacy [ Time Frame: 2-5 yrs. ] [ Designated as safety issue: No ]
    In subjects receiving PD, dialysis adequacy (Kt/Vurea) will be assessed at 4 weeks (visit 2), 12 weeks (visit 4) and then every 12 weeks (±14 days) until the end of the study (±14 days). Kt/Vurea target for PD patients is ≥ 1.7 per week. Kt/Vurea target for HD patients is ≥ 1.2 per dialysis session. Subjects who have a permanent modality transfer will be followed up for Kt/Vurea (with the frequency of assessment determined by the modality they are switched to) until the end of the study, transplantation, stopping dialysis, lost to follow-up, or death.

  • Co-morbidity Assessment [ Time Frame: 2-5 yrs. ] [ Designated as safety issue: No ]
    The Charlson Comorbidity Index contains 19 categories of comorbidity which are primarily defined using ICD-9-CM diagnoses codes, as well as a few procedure codes. The overall comorbidity score reflects the cumulative increased likelihood of one-year survival; the higher the score, the more severe the burden of comorbidity. Every diagnosis and procedure code is analyzed to see if it falls within one of the 16 comorbid conditions. In this study, the comorbidity assessment will be measured at visit 1, every 24 weeks (±14 days) after visit 1 to visit 23, and at the end-of-study visit.

  • Occurrence of Bacterial and Other Infections Infection rates [ Time Frame: 2-5 yrs. ] [ Designated as safety issue: Yes ]
    Occurrence of bacterial and other infections infection rates, especially regarding exit sites and peritoneal, will be monitored for HD and PD patients.

  • Hospitalization [ Time Frame: 2-5 yrs. ] [ Designated as safety issue: Yes ]
    Hospitalization rates and duration for each underlying reason will be monitored for HD and PD patients.

  • Transplantation Rate [ Time Frame: 2-5 yrs. ] [ Designated as safety issue: Yes ]
    Kidney transplantation is the best outcome that a patient can expect. By default, a patient will be discontinued from the study after transplantation. Imbalance of the transplantation rate between HD and PD will be assessed. However, all patients will be followed to the end of the study to assess the primary endpoint which is all-cause mortality.

  • Cause of Death [ Time Frame: 2-5 yrs. ] [ Designated as safety issue: Yes ]
    Cause of deaths due to acute myocardial infarction (AMI), congestive heart failure (CHF), infection (except peritonitis), peritonitis, malnutrition, stroke, cardiovascular and non-cardiovascular causes, etc., will be monitored for HD and PD patients

  • Change in Erythropoiesis-stimulating agent (ESA) [ Time Frame: 2-5 yrs. ] [ Designated as safety issue: No ]
    Dose changes in ESA dose will affect patient's status for anemia control, and will be monitored for HD and PD patients.

  • Change in blood pressure, hemoglobin, and S-phosphate [ Time Frame: 2-5 yrs. ] [ Designated as safety issue: Yes ]
    Blood pressure, hemoglobin, and S-phosphate will be monitored for HD and PD patients.

  • Subjective Global Assessment for Nutritional Status [ Time Frame: 2-5 yrs. ] [ Designated as safety issue: No ]
    Subjective Global Assessment (SGA) is a technique to assess a patient's nutritional status. The SGA will be measured by one dedicated, trained physician per site at visit 1, every 24 weeks (±14 days) from visit 1 to visit 23, and at the end-of-study visit.

  • Systemic inflammation as assessed by hs-CRP [ Time Frame: 2-5 yrs. ] [ Designated as safety issue: Yes ]
    Scores of systemic inflammation will be assessed using high-sensitivity C reactive protein (hs-CRP). Hs-CRP will be assessed at visits 1, 4-23, and at the end-of-study visit.

  • Quality of Life Quality of life (QOL) [ Time Frame: 2-5 yrs. ] [ Designated as safety issue: No ]
    Quality of Life Quality of life (QOL) will be assessed using the EQ-5D-3L (European Quality of Life - 5 Dimensions - 3L translation), the KDQoL-SF (Kidney Disease Quality of Life Short Form) questionnaires, and the Karnofsky Index. QOL will be assessed at visit 1, every 24 weeks (±14 days) from visit 1 to visit 23, and at the end-of-study visit.


Estimated Enrollment: 1370
Study Start Date: June 2011
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: ESRD patients receiving HD treatment
no investigational drug involved. Only oberseve therapy treatment
Other: Hemodialysis treatment
HD treatment
Experimental: ESRD patients receiving PD treatment
no investigational drug involved. Only oberseve therapy treatment
Other: Peritoneal Dialysis treatment
PD treatment

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects of either sex, aged 18 years or older at time of randomization.
  2. Subjects diagnosed with ESRD (glomerular filtration rate [GFR] ≤ 15 mL/min/m2 body surface area [BSA]) and predicted by the investigator to need dialysis therapy within 10 weeks after the pre-screening period.
  3. Subjects who, as judged by the investigator, are able to comprehend the pre-defined, standardized, modality education program and have undertaken this education during the screening period.
  4. Subjects, or their legal representative, who, as judged by the investigator, are capable of being trained for home-based PD.
  5. Subjects, or their legal representative, who are able to understand and voluntarily sign an ICF.
  6. Subjects who are able to adhere to the study visit schedule and other protocol requirements.
  7. Subjects who are able to regularly visit a HD center for HD therapy (≥ 3 times per week).
  8. Subjects who, as judged by the investigator, are expected to remain on dialysis for at least 48 weeks.
  9. Subjects who have normal liver function, as judged by the investigator.
  10. Female subjects of childbearing potential who have a negative serum or urine pregnancy test at screening. Sexually active women of childbearing potential must agree to use adequate contraceptive methods, as judged by the investigator, while in the study.

Exclusion Criteria:

  1. Subjects who are HIV positive.
  2. Subjects who have already received a permanent PD catheter or HD access that is intended for permanent use before receiving modality education or have already received permanent dialysis. Subjects are not excluded if an access is present within 4 weeks before screening for back-up purposes or for acute treatment of life-threatening uremic symptoms, electrolyte abnormalities, or fluid overload.
  3. Subjects who have a serious, uncontrolled medical disorder or active infection, which, as judged by the investigator, would jeopardize their ability to receive the prescribed dialysis treatment.
  4. Subjects who have dementia or a mental status that would significantly affect the subject's understanding of the Informed Consent Form (ICF).
  5. Subjects who are pregnant, intend to become pregnant during the study period, or are breast-feeding.
  6. Subjects with a history of drug (defined as illicit drug use) or alcohol (defined as regular or daily consumption of more than 4 alcoholic drinks per day) abuse in the 2 years before screening.
  7. Subjects who have previously received renal transplantation and are still being prescribed immunosuppressive therapy.
  8. Subjects who are currently using or have used an investigational product within five half-lives of the physiological action or 30 days, whichever is longer, before screening.
  9. Subjects who are unwilling or expected to be unable to fully comply with the visits and assessments required by the protocol.
  10. Subjects who have previously been randomized in this study.
  11. Subjects who are not eligible for either PD or HD, as judged by the investigator, due to:

    PD: documented extensive intra-peritoneal adhesions or other condition contraindicated for PD.

    HD: severe cardiac instability or other condition contraindicated for HD.

  12. Subjects who have a serious or acute condition that, as judged by the investigator, would preclude participation in the study.
  13. Subjects who have a malignancy requiring chemotherapy or radiation therapy.
  14. Subjects undergoing temporary dialysis treatment between the screening visit and Day 1 that is expected to exceed 6 weeks in duration.
  15. Subjects who have a life expectancy of less than 48 weeks.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01413074

Locations
China, Guangdong
The First Affiliated Hospital , Sun Yet-Sen University
Guangzhou, Guangdong, China, 510080
China, Shanghai
Renji Hospital , Shanghai Jiaotong University , School of Medicine
Shanghai, Shanghai, China
Ruijin Hospital,Shanghai Jiaotong University , School of Medicine
Shanghai, Shanghai, China, 200025
Shanghai Changzheng Hospital
Shanghai, Shanghai, China, 200003
Huashan Hospital ,Fudan University
Shanghai, Shanghai, China, 200040
China, Zhejiang
The First Affiliated Hospital , Zhejiang University, School of Medicine
Hangzhou, Zhejiang, China, 310003
Hangzhou Hospital of Tranditional Chinese Medicine
Hangzhou, Zhejiang, China, 310007
Sponsors and Collaborators
Baxter Healthcare Corporation
Investigators
Principal Investigator: Quian Jia-Qi, Prof. Shanghai Jiao Tong University School of Medicine
Principal Investigator: Yu Xue-qing, Prof. First Affiliated Hospital, Sun Yat-Sen University
  More Information

No publications provided

Responsible Party: Baxter Healthcare Corporation
ClinicalTrials.gov Identifier: NCT01413074     History of Changes
Other Study ID Numbers: CHN-RENAL-CTPIV-2010-106
Study First Received: June 16, 2011
Last Updated: April 7, 2014
Health Authority: China: Food and Drug Administration

Keywords provided by Baxter Healthcare Corporation:
End Stage Renal Disease
ESRD
Peritoneal Dialysis
PD
Hemodialysis
HD

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency

ClinicalTrials.gov processed this record on September 22, 2014